April 03, 2023 07:00 ET Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023 NEW YORK April 10, 2023 WebCoordinating between doctors, specialists, insurance, and hospitals, all while trying to understand your options and making the best decisions can be a daunting task. Cytokinetics To Participate In The 22nd Annual Needham By signing up you agree to receive content from us. View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005752/en/, Media Contact Tucker Hewes, Hewes Communications, Inc. (212) 207-9451 tucker@hewescomm.com, https://www.businesswire.com/news/home/20230110005752/en/, Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US, UPDATE 1-Turkey to raise corporate tax to fund earthquake rebuilding-draft law, UPDATE 1-Moderna starts application process for RSV vaccine approval in older adults, FOREX-Dollar steady before Fed minutes; yen hovers near 145-mark, UPDATE 1-Euro zone bond yields fall as economic activity contracts. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. For more information, visit www.pharming.com and find us on LinkedIn. ASRS - American Society of Retina Specialists - Annual Meeting. Such forward-looking statements are subject to a number of material risks and uncertainties including, but not limited to: the adequacy of Kinetas capital to support its future operations and its ability to successfully initiate and complete clinical trials; the difficulty in predicting the time and cost of development of Kinetas product candidates; Kinetas plans to research, develop and commercialize its current and future product candidates, including, but not limited to, KVA12123; the timing and anticipated results of Kinetas planned pre-clinical studies and clinical trials and the risk that the results of Kinetas pre-clinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials; the timing of the availability of data from Kinetas clinical trials; the timing of any planned investigational new drug application or new drug application; the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kinetas product candidates; Kinetas commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kinetas competitors and its industry; the impact of government laws and regulations; the timing and outcome of Kinetas planned interactions with regulatory authorities; Kinetas ability to protect its intellectual property position; Kinetas estimates regarding future revenue, expenses, capital requirements and need for additional financing; and those risks set forth under the caption Risk Factors in the Companys most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties and other important factors in Kinetas subsequent filings with the Securities and Exchange Commission. Contact:Cytokinetics Diane WeiserSenior Vice President, Corporate Communications, Investor Relations(415) 290-7757. 2nd Annual Mitochondria-Targeted Drug Development - February 24, 2022. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12123. Presenting companies represent multiple sectors, including: Communications & Enterprise Infrastructure, Semiconductors and Semiconductor Equipment. A live webcast of the presentation will be available Monday, April 17 at 9:30-10:10am ET. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase2bstudy for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Annual Healthcare Conference: Status: 2023-04-17 start The conference allows investors to begin the year by assessing the economic backdrop and emerging growth company landscape for 2023 and beyond. Conferences in Needham 2023/2024/2025 will bring speakers from Asia, Africa, North America, South America, Antarctica, Europe, and Australia. 22nd Annual Needham Virtual Healthcare Conference. 03/15/2023. Apr 18, 2023 at 2:15 PM EDT Listen to webcast. Pharming to present at the 22nd Annual Needham Virtual The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. For more information, please visit www.needhamco.com. Shattuck Labs, Inc. BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 1:30 p.m. Conferences in Needham 2023/2024/2025 It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. By providing your email address below, you are providing consent to Paragon 28 to send you the requested Investor Email Alert updates. NEW YORK, January 10, 2023--(BUSINESS WIRE)--Needham & Company will be holding its 25th Annual Needham Growth Conference ("NGC") from January 10-12, 2023. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. Instead, they are based on Kinetas current beliefs, expectations and assumptions regarding the future of Kinetas business, future plans and strategies, clinical results and other future conditions. 22nd Annual Needham Virtual Healthcare Conference. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook. Photos of eight activists who have been issued arrest warrants over national security are displayed during a press conference in Hong Kong, China July 3, 2023. Kineta to Present at 22nd Annual Needham Healthcare Conferences in Needham 2023/2024/2025 is an indexed listing of upcoming meetings, seminars, congresses, workshops, programs, continuing CME courses, trainings, summits, and weekly, annual or monthly symposiums. Needham & Company, LLC, a wholly owned subsidiary of The Needham Group, Inc., is a privately held, full-service investment bank that focuses exclusively on growth companies. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. April 17, 2023 11:00 AM ET. Viking Therapeutics to Present at 22nd Annual Needham Any forward-looking statement speaks only as of the date on which it was made. April 10, 2023 16:00 ET VK0214 is currently being evaluated in a Phase1bclinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. 01/10/23 Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023 | BioSpace Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023 Published: Apr 10, 2023 NASHVILLE, Tenn., (BUSINESS WIRE) -- Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham If you experience any issues with this process, please contact us for further assistance. Cytokinetics, Incorporated, South San Francisco, California, UNITED STATES. Needham Healthcare Conference Needham Zimmer Biomet to Present at the Needham Virtual SAN DIEGO, April 11, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, todayannounced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 22nd Annual Needham Healthcare Conference. KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. Forward-looking statements are neither historical facts nor assurances of future performance. Patient Advocates | Health Care Connect | NJ, NY, PA, CT Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com, Media Contact:Sheryl SeapyReal Chemistry949-903-4750sseapy@realchemistry.com. Cytokinetics is developing aficamten, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Anavex Life Sciences to Present at the 22nd Annual Needham TSLA + Free Alerts. Cision Distribution 888-776-0942 April 20, 2023 at 8:00 AM EDT Click here for webcast. Looking for health conferences events in Needham? When typing in this field, a list of search results will appear and be automatically updated as you type. The webcast presentation replay will be available for viewing on the Events & Presentations section of the Company's website. In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness. WARSAW, Ind., April 4, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members Our events range from sector-specific conferences, roadshows, industry expert events, conference calls to bespoke trips organized by our corporate access team. 22nd Annual Needham Virtual Healthcare Conference. Investor Material News provided by. The conference will take place April 17-20, 2023. Pharming Group, Leiden, The NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696, Heather Robertson, Investor Relations & Corporate Communications ManagerE: [emailprotected], FTI Consulting, London, UKVictoria Foster Mitchell/Alex Shaw/Amy ByrneT: +44 203 727 1000, LifeSpring Life Sciences Communication, Amsterdam, The NetherlandsLeon MelensT: +31 6 53 81 64 27E: [emailprotected], Logo - https://mma.prnewswire.com/media/2003587/Pharming_Group_Logo.jpg. ANAVEX2-73 AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints. Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference. Healthcare Pharming's management will be available for one-to-one investor meetings during the conference. Needham Hong Kong Police Issue Arrest Warrants for Eight Activists Shattuck Labs, Inc. AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 22nd Annual Needham Virtual Healthcare Conference being held April 17-20, 2023. Compounds derived from Shattucks proprietary Agonist Redirected Checkpoint, ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. The Bioprocessing Summit 14-17 August 2023 (Healthcare Conference in Needham, USA) Gene Therapy Potency Assay Summit 29-31 August 2023 5th Exosome NGC, Needham & Companys flagship conference, is one of the largest growth stock investing events in the country, with over 375 companies participating in 2023. 22nd Annual Needham Virtual Healthcare Conference | PepGen About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. April 20, 2023 10:15 AM ET. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Needham Healthcare Conference. For more information, please visit: www.ShattuckLabs.com. 2023 Copyright Solebury Strategic Communications | Source: After submitting your request, you will receive an activation email to the requested email address. A live webcast of the fireside chat will be available on the Investors section of the Companys website. For more information about Viking Therapeutics, please visitwww.vikingtherapeutics.com. ET. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Annexon Biosciences. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. ET. A replay of the webcast will be archived for up to 90 days following the presentation date. Details for this presentation are as follows: 22nd Annual Needham Healthcare Conference. Needham Conferences & Events. For more information, please call (212) 371-8300 or visit www.needhamco.com. Company management will also be available for virtual one-on-one meetings. Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Needham CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Next higher product group: Needham & Co. Annexon Biosciences to Participate in the 22nd Annual KVA12123 (formerly referred to as KVA12.1) is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. Pediatric Urgent Care | PM Pediatric Care Cytokinetics, Incorporated The 21st Annual Needham Virtual Healthcare Conference took place April 11-14, 2022 and featured fireside chats and presentations from leading public and private Big North Conference (BNC) Executive Director - Sharon Hughes - Conferences Pharming's CEO, Sijmen de Vries, will present on April 20 at 08:00 ET / 14:00 CEST. 21st Annual Needham Virtual Healthcare Conference SEATTLE, April 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel , . In addition to investment banking, Needham & Companys activities include institutional sales and trading, and asset management. Needham The use of words such as, but not limited to, believe, expect, estimate, project, intend, future, potential, continue, may, might, plan, will, should, seek, anticipate, or could and other similar words or expressions are intended to identify forward-looking statements. Shattuck has offices in both Austin, Texas and Durham, North Carolina. Needham